Company intelligence / Profile preview

SoniVie

Ownership: Private
Development stage: Phase 3

Overview

SoniVie's TIVUS system is an investigational intravascular ultrasound device designed to ablate sympathetic nerves via a minimally invasive procedure. Early clinical studies and a U.S./Israel IDE pilot trial have shown the technology can safely reduce blood pressure in patients with uncontrolled or resistant hypertension. The company has initiated a global pivotal THRIVE study and received three FDA Breakthrough Device Designations. Clinical programs are also underway for pulmonary artery denervation and lung denervation, targeting additional hypertensive disorders.

Therapeutic areas: PulmonologyCardiovascular
Modalities: DeviceUltrasound-based therapy (Therapeutic Intra-Vascular Ultrasound)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

TIVUS

Phase 3

Indications: Hypertension, Pulmonary hypertension

Partnerships

Boston Scientific

Beyond the preview

Go deeper on SoniVie.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SoniVie.

Explore the full profile